Vimarsana
Biggest News Aggregation in the World

Page 7 - Ir Team News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ir Team. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ir Team Today - Breaking & Trending Today

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon Group Publishes 2022 Annual Report - Vimarsana News

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon Group Publishes 2022 Annual Report

Investegate announcements from Etalon Group PLC, Etalon Group Publishes 2022 Annual Report

Junshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma - Vimarsana News

Junshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma

SHANGHAI, China, April 27, 2023 -- Shanghai Junshi Biosciences Co., Ltd , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of... | April 27, 2023

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma - Vimarsana News

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon Announces Changes to Board of Directors - Vimarsana News

Investegate |Etalon Group PLC Announcements | Etalon Group PLC: Etalon Announces Changes to Board of Directors

Investegate announcements from Etalon Group PLC, Etalon Announces Changes to Board of Directors

Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung Cancer (NSCLC) in Phase 3 Neotorch Study - Vimarsana News

Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung Cancer (NSCLC) in Phase 3 Neotorch Study

Perioperative toripalimab plus chemotherapy significantly improved EFS and reduced risk of disease recurrence, progression events or death by 60% among resectable stage III NSCLC patients, compared to